Literature DB >> 31376570

Preferential uptake of chitosan-coated PLGA nanoparticles by primary human antigen presenting cells.

Verónica Durán1, Hanzey Yasar2, Jennifer Becker1, Durairaj Thiyagarajan2, Brigitta Loretz2, Ulrich Kalinke3, Claus-Michael Lehr4.   

Abstract

Biodegradable polymeric nanoparticles (NP) made from poly (lactid-co-glycolide) acid (PLGA) and chitosan (CS) hold promise as innovative formulations for targeted delivery. Since interactions of such NP with primary human immune cells have not been characterized, yet, here we assessed the effect of PLGA or CS-PLGA NP treatment on human peripheral blood mononuclear cells (PBMC), as well as on monocyte-derived DC (moDC). Amongst PBMC, antigen presenting cells (APC) showed higher uptake of both NP preparations than lymphocytes. Furthermore, moDC internalized CS-PLGA NP more efficiently than PLGA NP, presumably because of receptor-mediated endocytosis. Consequently, CS-PLGA NP were delivered mostly to endosomal compartments, whereas PLGA NP primarily ended up in lysosomes. Thus, CS-PLGA NP confer enhanced delivery to endosomal compartments of APC, offering new therapeutic options to either induce or modulate APC function and to inhibit pathogens that preferentially infect APC.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chitosan-PLGA NP; Intracellular trafficking; Monocyte-derived DC; Nanoparticles; PBMC; PLGA NP

Mesh:

Substances:

Year:  2019        PMID: 31376570     DOI: 10.1016/j.nano.2019.102073

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  13 in total

Review 1.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

Review 2.  Recent advances in nanoplatforms for the treatment of neuropathic pain.

Authors:  Beibei Yu; Kunzhe Wu; Xiaohua Xu; Yan Liu; Jinlan Jiang
Journal:  Spinal Cord       Date:  2022-01-27       Impact factor: 2.473

Review 3.  PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery.

Authors:  Violet V Sheffey; Emily B Siew; Eden E L Tanner; Omolola Eniola-Adefeso
Journal:  Adv Healthc Mater       Date:  2022-01-27       Impact factor: 11.092

4.  Nanoparticles of Chitosan/Poly(D,L-Lactide-Co-Glycolide) Enhanced the Immune Responses of Haemonchus contortus HCA59 Antigen in Model Mice.

Authors:  Qiangqiang Wang; Xiaoke Sun; Xin Huang; Jianmei Huang; Muhammad Waqqas Hasan; RuoFeng Yan; Lixin Xu; Xiaokai Song; Xiangrui Li
Journal:  Int J Nanomedicine       Date:  2021-05-04

5.  Liposomal Delivery of Mycophenolic Acid With Quercetin for Improved Breast Cancer Therapy in SD Rats.

Authors:  Gopal Patel; Neeraj Singh Thakur; Varun Kushwah; Mahesh D Patil; Shivraj Hariram Nile; Sanyog Jain; Uttam Chand Banerjee; Guoyin Kai
Journal:  Front Bioeng Biotechnol       Date:  2020-06-16

Review 6.  Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement.

Authors:  Atin Khalaj-Hedayati; Caroline Lin Lin Chua; Peter Smooker; Khai Wooi Lee
Journal:  Influenza Other Respir Viruses       Date:  2019-11-27       Impact factor: 4.380

Review 7.  Polymeric nanoparticle vaccines to combat emerging and pandemic threats.

Authors:  David Wibowo; Sytze H T Jorritsma; Zennia Jean Gonzaga; Benjamin Evert; Shuxiong Chen; Bernd H A Rehm
Journal:  Biomaterials       Date:  2020-12-10       Impact factor: 12.479

8.  A Multiepitope Peptide, rOmp22, Encapsulated in Chitosan-PLGA Nanoparticles as a Candidate Vaccine Against Acinetobacter baumannii Infection.

Authors:  Xingran Du; Jianpeng Xue; Mingzi Jiang; Shaoqing Lin; Yuzhen Huang; Kaili Deng; Lei Shu; Hanmei Xu; Zeqing Li; Jing Yao; Sixia Chen; Ziyan Shen; Ganzhu Feng
Journal:  Int J Nanomedicine       Date:  2021-03-04

Review 9.  Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic.

Authors:  Concetta Di Natale; Sara La Manna; Ilaria De Benedictis; Paola Brandi; Daniela Marasco
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

10.  Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement.

Authors:  Yongqing Liu; Xiaoli Wang; Jiangfei Zhou; Shuaibing Shi; Tengfei Shen; Liangliang Chen; Min Zhang; Chengshui Liao; Chen Wang
Journal:  Front Immunol       Date:  2021-07-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.